作者: James H O’Keefe , James J DiNicolantonio , Carl J Lavie , David SH Bell ,
DOI: 10.17925/USE.2014.10.01.68
关键词:
摘要: The US Food and Drink Administration (FDA) recently published a warning that statin usage may increase the risk for type 2 diabetes. However, incidence of new-onset diabetes varies substantially among clinical trials investigating efficacy safety statins. Meta-analyses indicate therapy is associated with an increased approximately 9 %. incident be higher doses potencies Mechanisms explaining potentially have not been fully elucidated, statins differ considerably in terms their effect on glucose metabolism ultimately It widely accepted cardiovascular benefits use greatly outweigh risks different glycemic parameters influence choice those factors Unlike other stains, pitavastatin raises adiponectin levels, which turn lowers insulin resistance improves secretion. Furthermore, numerous studies concluded pravastatin do affect control favorable treatment options patients with, or at for,